Harbour BioMed Launches Fully Human Generative AI HCAb Model

Harbour BioMed has launched its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIx AI platform, announced in a press release. The model was unveiled during the company’s Global R&D Day 2025 event in Shanghai.

The AI HCAb Model integrates sequence generation, intelligent screening, and wet-lab validation into a closed-loop workflow. Trained on nine million HCAb sequences and public data, it uses a fine-tuned protein language model to design and optimize antibody sequences. Candidates that meet stability and developability criteria are synthesized and validated experimentally.

According to the company, the model achieved a tenfold increase in candidate generation and a 78.5% success rate in target binding. Twenty molecules underwent additional laboratory validation, showing high activity, purity, and yield, with nanomolar-level binding affinities.

Harbour BioMed also announced the formation of the Global AI + Pharmaceutical Ecosystem Alliance at the same event. The alliance includes industry partners such as Insilico Medicine, Evinova, and Deep Intelligent Pharma, aiming to advance AI-driven drug discovery and development.